Etoricoxib Co-Grinding: Unlocking New Frontiers in Drug Solubility | ||||
| Journal of Advanced Medical and Pharmaceutical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 16 May 2025 PDF (605 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jampr.2025.371951.1095 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Fatma Sakr1; Doaa A. Habib   1, 2; Haidy A. Abass 1; Heba M Elbedaiwy1
| ||||
| 1Department of Pharmaceutics, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt. | ||||
| 2Department of Pharmaceutics and Pharmaceutical Technology, Alsalam University in Egypt, Kafr Al Zaiyat, Egypt | ||||
| Abstract | ||||
| The classification of etoricoxib (ETX), a nonsteroidal anti-inflammatory drug, under the Biopharmaceutics Classification System as a model class II drug is based on its low solubility and slow dissolution rate, which limits its bioavailability and therapeutic efficacy. This study aimed to improve the dissolution rate and consequently the anti-inflammatory efficacy of etoricoxib. A mixture of etoricoxib with different co-formers, L-alanine, L-glycine and sucralose, has been developed in three ratios (1:1, 1:2, and 1:4) by the liquid assisted grinding. All formulations underwent in-vitro dissolution testing to assess their effectiveness in improving drug solubility. Among the tested co-formers, sucralose demonstrated a significant enhancement in etoricoxib dissolution. The in-vitro characterization revealed enhancement in the solubility properties of ETX, which may have led to a better dissolution profile. The formula consisting of etoricoxib and sucralose at a 1:4 ratio was identified as the targeted formula with the desired characteristics, making it the ideal formulation for further investigation. | ||||
| Keywords | ||||
| Etoricoxib; Co-grinding; solubility; Dissolution | ||||
|
Statistics Article View: 130 PDF Download: 93 |
||||
